Clinical trial
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic…
NCT00185302 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00185302 |
|---|---|
| Title | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma |
| Official title | Phase II Study of MS-275, a Histone Deacetylase Inhibitor, Comparing 2 Dosage Schedules in Patients With Metastatic Melanoma |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894) |
| Enrollment | 28 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 14, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: